Efficacy and safety of bevacizumab in the treatment of human epidermal growth factor receptor type 2 negative metastatic breast cancer: About a large series in moroccan population

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Efficacy And Safety ◽

Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

JAMA Network Open ◽

10.1001/jamanetworkopen.2019.16211 ◽

2019 ◽

Vol 2 (11) ◽

pp. e1916211 ◽

Cited By ~ 3

Author(s):

Neil M. Iyengar ◽

Lillian M. Smyth ◽

Diana Lake ◽

Ayca Gucalp ◽

Jasmeet C. Singh ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Efficacy And Safety ◽

Human Epidermal Growth Factor ◽

Phase I study of weekly nab ‐paclitaxel combined with S‐1 in patients with human epidermal growth factor receptor type 2‐negative metastatic breast cancer

Cancer Science ◽

10.1111/cas.12658 ◽

2015 ◽

Vol 106 (6) ◽

pp. 734-739 ◽

Cited By ~ 6

Author(s):

Junji Tsurutani ◽

Katsumasa Kuroi ◽

Tsutomu Iwasa ◽

Masaki Miyazaki ◽

Shinichi Nishina ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase I Study ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer

The Breast Journal ◽

10.1111/tbj.13516 ◽

2020 ◽

Vol 26 (3) ◽

pp. 368-375

Author(s):

Karen A. Gelmon ◽

Massimo Cristofanilli ◽

Hope S. Rugo ◽

Angela M. DeMichele ◽

Anil A. Joy ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Efficacy And Safety ◽

Hormone Receptor Positive ◽

Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)

European Journal of Cancer ◽

10.1016/j.ejca.2021.05.025 ◽

2021 ◽

Vol 153 ◽

pp. 223-233

Author(s):

Volkmar Mueller ◽

Andrew Wardley ◽

Elisavet Paplomata ◽

Erika Hamilton ◽

Amelia Zelnak ◽

...

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Neoadjuvant chemotherapy with biosimilar trastuzumab in human epidermal growth factor receptor 2 overexpressed non-metastatic breast cancer: patterns of use and clinical outcomes in India

ecancermedicalscience ◽

10.3332/ecancer.2021.1207 ◽

2021 ◽

Vol 15 ◽

Author(s):

Anjana Joel ◽

Josh Thomas Georgy ◽

Divya Bala Thumaty ◽

Ajoy Oommen John ◽

Raju Titus Chacko ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Neoadjuvant Chemotherapy ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Patterns Of Use ◽

Phase II Study of Eribulin Mesylate Administered Biweekly in Patients With Human Epidermal Growth Factor Receptor-2–negative Metastatic Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2019.09.007 ◽

2020 ◽

Vol 20 (2) ◽

pp. 160-167

Author(s):

John Smith ◽

Amy Irwin ◽

Lori Jensen ◽

Karen Tedesco ◽

Soamnauth Misir ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Eribulin Mesylate ◽

Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC): results From a Multicenter Retrospective Analysis

Annals of Oncology ◽

10.1093/annonc/mdw337.21 ◽

2016 ◽

Vol 27 ◽

pp. iv65

Author(s):

L. Pizzuti ◽

I. Sperduti ◽

A. Michelotti ◽

C. Omarini ◽

T. Gamucci ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Chromosome 17 Polysomy without Human Epidermal Growth Factor Receptor 2 Amplification Does Not Predict Response to Lapatinib Plus Paclitaxel Compared with Paclitaxel in Metastatic Breast Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-09-1643 ◽

2010 ◽

Vol 16 (4) ◽

pp. 1281-1288 ◽

Cited By ~ 27

Author(s):

L. Downey ◽

R. B. Livingston ◽

M. Koehler ◽

M. Arbushites ◽

L. Williams ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Chromosome 17 ◽

Human Epidermal Growth Factor ◽

Abstract P1-09-01: A phase 1b study of abemaciclib plus pembrolizumab for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC)

10.1158/1538-7445.sabcs17-p1-09-01 ◽

2018 ◽

Cited By ~ 4

Author(s):

HS Rugo ◽

P Kabos ◽

MN Dickler ◽

WJ John ◽

I Smith ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Hormone Receptor Positive ◽

Phase 1B ◽

Abstract P3-04-03: Identification, clinical characteristics and treatment outcomes of somatic human epidermal growth factor receptor 2 (ERBB2) mutations in metastatic breast cancer patients

10.1158/1538-7445.sabcs17-p3-04-03 ◽

2018 ◽

Author(s):

L Jongen ◽

G Floris ◽

D Lambrechts ◽

A Laenen ◽

P Neven ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Clinical Characteristics ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Breast Cancer Patients ◽